Introduction/Overview
Natural products are an important source of new drug discovery and development, among which medicinal plants have attracted much attention due to their long history of application and rich chemical diversity. Epimedium spp., as a traditional Chinese medicinal herb for tonifying the kidneys, strengthening yang, strengthening tendons and bones, has been extensively studied in modern pharmacology for its wide-ranging activities in anti-tumor, anti osteoporosis, neuroprotection, and immune regulation. These activities are mainly attributed to their rich flavonoid components, especially icariin compounds. Sagittatoside A (CAS number: 118525-35-2) is a flavonol glycoside with significant biological activity isolated from Epimedium plants. In recent years, with the deepening of research on the pathogenesis of malignant tumors, especially lung cancer, the search for efficient and low toxicity new therapeutic drugs has become a research hotspot. Jianhuo glycoside A has emerged as a potential candidate molecule in the field of natural product anti-tumor research due to its multi-target and multi pathway inhibitory activity demonstrated in tumor models such as lung cancer. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, especially the mechanism of its anti lung cancer effect and molecular target network of Arrowhead A, and evaluate and prospect its pharmacological properties and clinical application prospects.
Chemical structure and physicochemical properties
Jianhuo glycoside A is a flavonol glycoside compound, whose chemical structure is a glycosylated derivative of Icariside II. Its molecular formula is C33H40O15 and its molecular weight is 676.6680. Its core structure is the flavonol core, with glycosidic chains connected at positions 3 and 7, respectively. Specifically, it is connected to a rhamnose group at position 3 and a glucose group at position 7, with the end of the glucose group further connected to a p-hydroxycinnamoyl group. This unique acylated glycoside structure is a key characteristic that distinguishes it from other icariin compounds, such as icariin, and profoundly affects its physicochemical properties and biological activity.
From the analysis of parameters related to drug properties, the lipid water partition coefficient (LogP) of Arrowroot Glycoside A is 1.2673, indicating that it has a certain degree of lipophilicity, but not highly hydrophobic. Its topological polar surface area (TPSA) is as high as 238.2000 Å ², mainly attributed to the abundant hydroxyl, glycosidic oxygen atoms, and ester carbonyl groups in the molecule, which are potential hydrogen bond donors and acceptors. A higher TPSA is usually unfavorable for passive transmembrane diffusion. Its water solubility value is 1.6177 (usually measured in mg/mL or logS), indicating that it has some solubility in water, but may still belong to the category of slightly soluble or poorly soluble. Based on the comprehensive analysis of LogP and TPSA, it meets a few criteria in the Rule of Five, but its higher molecular weight and TPSA may affect its oral bioavailability. In addition, the prediction shows that its blood-brain barrier permeability is low, which limits its direct effects on central nervous system related diseases, but may also reduce the risk of central neurotoxicity. In the early toxicity warning indicators, the hERG inhibition risk is "no", and the Ames test result is 0.0 (usually indicating no mutagenicity), which provides preliminary positive signals for its safety.
Plant sources and extraction methods
Arrowhead A is mainly derived from various plants in the Epimedium genus of the Berberidaceae family, such as Epimedium koreanum Nakai, Epimedium pubescens Maxim., and Epimedium sagittatum (Sieb. et Zucc.) Maxim. Its name "Arrowhead" is derived from Epimedium sagittatum. In plants, it often coexists with other icariin compounds such as icariin and chaohuoding.
Its extraction and separation usually follow the conventional process of natural product chemistry. Firstly, the dried above ground parts of Epimedium are crushed and subjected to reflux extraction or ultrasound assisted extraction using alcohol solvents (such as methanol, ethanol) or alcohol water mixed solvents to obtain the crude extract of total flavonoids. Subsequently, the target components were enriched by liquid-liquid extraction using organic solvents such as ethyl acetate and n-butanol. Further purification relies on various chromatographic techniques. Macroporous adsorption resin column chromatography (such as D101, AB-8) is often used for preliminary separation, and then silica gel column chromatography, reverse phase silica gel column chromatography (such as ODS C18), dextran gel column chromatography (such as Sephadex LH-20) are used for repeated separation. High performance liquid chromatography (HPLC), especially preparative HPLC, is a key technology for obtaining high-purity Arrowroside A monomers. Modern technologies such as high-speed countercurrent chromatography (HSCCC) have also been applied for the separation of such compounds due to their high efficiency and avoidance of irreversible adsorption by solid adsorbents. The optimization of extraction process (such as solvent ratio, temperature, time) and the exploration of chromatographic conditions (such as mobile phase system, gradient elution program) are the key to obtaining high yield and high purity of arrowroot glycoside A.
Pharmacological activity research
Jianhuo glycoside A exhibits a wide range of pharmacological activities, among which anti-tumor activity is the most prominent, especially accumulating a lot of evidence in lung cancer research.
-
Antitumor activity A large number of in vitro studies have shown that icariin A has significant inhibitory and pro apoptotic effects on various lung cancer cell lines, such as A549, NCI-H460, NCI-H1975, etc. Its intensity of action often exhibits dose and time dependence. In animal models, administration of arrowroot glycoside A can effectively inhibit the growth of nude mouse transplanted tumors (such as A549 cell transplanted tumors), reduce tumor volume and weight, and does not show significant systemic toxicity within a certain dose range, indicating that it has a good therapeutic window.
-
Anti inflammatory and immune regulatory activity Inflammation is closely related to the occurrence and development of tumors. Arrowhead A has been shown to inhibit macrophage inflammatory responses induced by lipopolysaccharides (LPS) and reduce the production of inflammatory factors such as nitric oxide (NO), tumor necrosis factor - α (TNF - α), and interleukin-6 (IL-6). This anti-inflammatory effect may be related to its regulation of the tumor microenvironment and indirect inhibition of tumor progression.
-
Other potential activities Based on the traditional efficacy of total flavonoids in Epimedium, Atractylodes macrocephala A may also play a role in anti osteoporosis, neuroprotection, and cardiovascular protection. However, there is relatively little specialized research on these activities targeting this monomeric compound, and its contribution needs further clarification.
Mechanism of action and molecular targets
The anti lung cancer effect of Jianhuo glycoside A is not achieved through a single pathway, but involves a complex multi-target regulatory network, which may be related to its chemical structure participating in multiple molecular interactions. Existing research has revealed its interactions with multiple key target proteins, mainly focusing on inhibiting cell proliferation, inducing cell apoptosis, inhibiting invasion and metastasis, and regulating the tumor microenvironment.
-
Inducing cell apoptosis and regulating apoptosis related proteins：
- BCL2 family BCL2 is an important anti apoptotic protein. Jianhuo glycoside A can downregulate the expression of BCL2 and may upregulate the expression of pro apoptotic proteins such as BAX, leading to a decrease in mitochondrial membrane potential and release of cytochrome C, thereby activating the Caspase cascade reaction and ultimately inducing apoptosis in lung cancer cells.
- STAT3 signaling pathway Signal transduction and transcription activator 3 (STAT3) is a core regulatory factor for tumor cell survival, proliferation, and immune escape. Jianhuo glycoside A can effectively inhibit the phosphorylation (activated form) of STAT3, block its nuclear translocation and the transcription of downstream target genes (such as Cyclin D1, Survivor, BCL2, etc.), thereby inhibiting cell proliferation and promoting apoptosis.
-
Inhibition of cell proliferation and cycle arrest：
- TOP2A Topoisomerase II alpha (TOP2A) is an enzyme essential for DNA replication and cell division, and is also a target of various chemotherapy drugs. Jianhuo glycoside A may inhibit TOP2A activity, causing DNA double strand breaks that cannot be repaired, thereby preventing cell cycle progression and inducing cell death.
- PI3K/Akt pathway Phosphatidylinositol 3-kinase catalytic subunit gamma (PIK3CG) is a key component of the PI3K/Akt signaling pathway. The overactivation of this pathway is closely related to tumor growth, survival, and drug resistance. Arrow gourd glycoside A may inhibit the phosphorylation of PIK3CG or its downstream Akt, thereby suppressing its pro survival and proliferation signals.
-
Inhibit tumor invasion and metastasis：
- MMP2 Matrix metalloproteinase 2 (MMP2) can degrade extracellular matrix and plays a crucial role in tumor invasion and metastasis. Jianhuo glycoside A can downregulate the expression and activity of MMP2, thereby inhibiting the migration and invasion ability of lung cancer cells.
- MAPT The abnormal expression of microtubule associated protein Tau (MAPT) is associated with cytoskeleton remodeling and tumor metastasis. Arrow gourd glycoside A may interfere with cell motility by affecting the function of MAPT.
-
Regulating tumor microenvironment and immune response：
- TLR4/NF - κ B pathway Toll like receptor 4 (TLR4) and its downstream nuclear factor kappa B (NF - κ B, key subunit RELA/p65) are important bridges connecting inflammation and tumors. Jianhuo glycoside A can inhibit TLR4 signaling, block NF - κ B activation, thereby reducing the production of a series of pro-inflammatory, pro survival, and pro metastatic factors and improving the tumor microenvironment.
- ABCA1 ATP binding cassette transporter A1 (ABCA1) is involved in cholesterol efflux and its function is related to cell membrane fluidity, signal transduction, and immune regulation. In tumors, ABCA1 may affect the lipid metabolism and immunogenicity of tumor cells. The regulatory effect of Jianhuo glycoside A on ABCA1 and its significance in anti-tumor treatment are being explored.
- ESR2 Estrogen receptor beta (ESR2) is often expressed in non-small cell lung cancer, and its signaling is context dependent, which may affect cell proliferation and apoptosis. It is worth further studying whether Arrowroot Glycoside A regulates the ESR2 pathway as a plant estrogen like substance.
In summary, arrowroot glycoside A forms a synergistic network by simultaneously acting on multiple targets such as BCL2, STAT3, TOP2A, PIK3CG, MMP2, TLR4/RELA, jointly inhibiting the growth, survival, invasion, and metastasis of lung cancer, and regulating the immune microenvironment. This multi-target characteristic is its advantage as a natural product derivative, but it also increases the complexity of its mechanism research.
Evaluation of drug properties and pharmacokinetics
Despite exhibiting good anti-tumor activity in vitro and animal models, the drug development of Arrowroot Glycoside A still faces some challenges, and its pharmacokinetic properties are the key to determining its successful development.
-
Absorption, distribution, metabolism, excretion (ADME)：
- absorb As a glycoside compound with medium molecular weight and high TPSA, the oral absorption of arrowroot glycoside A may be limited. The glycoside hydrolases and gut microbiota in the intestine may hydrolyze it into aglycones (such as deacetylated products or icariin II), and the activity and pharmacokinetic behavior of these metabolites may differ from the prototype drug, constituting its complex in vivo fate.
- distribution The predicted blood-brain barrier permeability is low, indicating that it is mainly distributed in peripheral tissues and organs. Its accumulation ability in tumor tissue needs to be experimentally verified.
- Metabolism The liver is its main metabolic site and may undergo phase I metabolism (such as oxidation and reduction) and phase II metabolism (such as glucuronidation and sulfation). The cytochrome P450 enzyme system may be involved.
- excretion The prototype drug and its metabolites may be primarily excreted through the kidneys (urine) and/or bile (feces).
-
Optimization strategy for drug properties：
- Prodrug design To address the issue of insufficient solubility and permeability, methods such as esterification of hydroxyl groups, preparation of phospholipid complexes or amino acid ester prodrugs can be used to improve their lipid solubility and membrane permeability, thereby enhancing oral bioavailability.
- Nano delivery system Using nanocarriers such as liposomes, polymer nanoparticles, and micelles to encapsulate icariin A can enhance its water solubility, protect it from premature metabolism, and target tumor tissues through enhanced penetration and retention (EPR) effects, improving therapeutic efficacy and reducing systemic toxicity.
- Structural modification Structural modification of its sugar or acyl groups to optimize its ADME properties while preserving its pharmacophore is an important direction in pharmaceutical chemistry research.
At present, there is still a relative lack of research data on the pharmacokinetics of Arrowhead A system, and it is urgent to conduct in-depth in vivo ADME research to provide a basis for its dosage form design and clinical administration plan.
Clinical application prospects and prospects
Jianhuo glycoside A, as a natural compound with multi-target anti lung cancer activity, has broad clinical application prospects, but the road ahead is long.
- Direct anti-tumor therapy It is expected to be developed as a new type of anti lung cancer drug, especially suitable for patients who are resistant to traditional chemotherapy or cannot tolerate toxic side effects. Its multi-target characteristics may help overcome the problem of resistance that single target drugs are prone to.
- Combination therapy sensitizer Given that its mechanism of action differs or complements multiple chemotherapy drugs (such as topoisomerase inhibitors, platinum based drugs) and targeted drugs, the combination of icariin A with existing standard therapies may produce synergistic effects, reduce chemotherapy drug dosage, improve efficacy, and reverse drug resistance.
- Adjuvant treatment and prevention Its anti-inflammatory and immunomodulatory effects suggest that it may be used as an adjuvant therapy for lung cancer to improve patients' quality of life, or for chemoprevention in high-risk populations.
However, in order to achieve its clinical translation, future research needs to focus on the following directions:
* In depth mechanism research Using chemical biology methods such as affinity fishing, molecular docking, and gene editing techniques to more accurately identify its direct target and elucidate the cross dialogue between its multi-target network.
* Systematic evaluation of drug properties Conduct comprehensive preclinical pharmacokinetic and toxicological studies, clarify the safe dose range, major toxic target organs, and metabolic characteristics.
* Innovative formulation development Vigorously promote the development of new delivery systems based on nanotechnology or prodrug strategies to solve the bottleneck problem of low bioavailability.
* Explore biomarkers Search for biomarkers (such as the expression levels of specific target proteins) that can predict the therapeutic response of Atractylodes macrocephala A to guide personalized medication.
Conclusion
Jianhuo glycoside A is an active natural product discovered from the traditional Chinese medicine Epimedium. It exhibits great potential for multi pathway inhibition in the treatment of lung cancer by regulating multiple key targets such as BCL2, STAT3, TLR4/NF - κ B, PI3K/Akt, TOP2A, etc. Although significant progress has been made in its chemical structure, pharmacological activity, and preliminary mechanism research, its relatively poor pharmacokinetic parameters (such as high TPSA and low BBB permeability) and incomplete pharmacokinetic characteristics pose the main challenges for its clinical drug translation. In the future, through interdisciplinary collaboration, combined with modern research methods in medicinal chemistry, pharmacy, and pharmacology, the molecular mechanism will be deeply revealed, and reasonable structural optimization or dosage form innovation will be carried out to address its shortcomings. It is expected that the ancient plant molecule of arrowroot glycoside A will be transformed into a new anti-tumor drug candidate with modern medical value, providing new treatment options for lung cancer patients.
